Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Alnylam Pharma (0HD2) Stock Price & Analysis
0 Followers
0HD2 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$119.30 - $241.06
Previous Close$194.96
Volume266.00
Average Volume (3M)299.00
Market Cap
$24.32B
Enterprise Value$23.35B
Total Cash (Recent Filing)$2.19B
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)N/A
Beta0.19
Next Earnings
Apr 27, 2023EPS Estimate
-$1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding124,130,988
10 Day Avg. Volume45
30 Day Avg. Volume299
Standard Deviation0.15
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-149.05
Price to Sales (P/S)17.93
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-38.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.51
Enterprise Value/Gross Profit26.88
Enterprise Value/Ebitda-26.37
Forecast
1Y Price Target
$247.94Price Target Upside27.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Alnylam Pharma News
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $119.30 and its highest was $241.06 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Apr 27, 2023 which is in 26 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 23, 2023. The company reported -$1.68 earnings per share for the quarter, beating the consensus estimate of -$1.859 by $0.179.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$1.67.
How many shares outstanding does Alnylam Pharmaceuticals have?
Currently, no data Available
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$1.68 in its last earnings report, beating expectations of -$1.859. Following the earnings report the stock price went down -3.393%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 1B.
---
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$247.94 (27.18% Upside)
$247.94 (27.18% Upside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $361.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.49%
12-Months-Change
Fundamentals
Return on Equity
-526.14%
Trailing 12-Months
Asset Growth
-2.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
---